JP2016507521A5 - - Google Patents

Download PDF

Info

Publication number
JP2016507521A5
JP2016507521A5 JP2015555498A JP2015555498A JP2016507521A5 JP 2016507521 A5 JP2016507521 A5 JP 2016507521A5 JP 2015555498 A JP2015555498 A JP 2015555498A JP 2015555498 A JP2015555498 A JP 2015555498A JP 2016507521 A5 JP2016507521 A5 JP 2016507521A5
Authority
JP
Japan
Prior art keywords
seq
binding protein
sequence shown
disease
motomeko
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015555498A
Other languages
English (en)
Japanese (ja)
Other versions
JP6539585B2 (ja
JP2016507521A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2014/000066 external-priority patent/WO2014117220A1/en
Publication of JP2016507521A publication Critical patent/JP2016507521A/ja
Publication of JP2016507521A5 publication Critical patent/JP2016507521A5/ja
Application granted granted Critical
Publication of JP6539585B2 publication Critical patent/JP6539585B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015555498A 2013-02-01 2014-01-31 抗cd83抗体及びその使用 Expired - Fee Related JP6539585B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361759780P 2013-02-01 2013-02-01
US61/759,780 2013-02-01
PCT/AU2014/000066 WO2014117220A1 (en) 2013-02-01 2014-01-31 Anti-cd83 antibodies and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019000340A Division JP2019076102A (ja) 2013-02-01 2019-01-04 抗cd83抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2016507521A JP2016507521A (ja) 2016-03-10
JP2016507521A5 true JP2016507521A5 (https=) 2017-02-23
JP6539585B2 JP6539585B2 (ja) 2019-07-03

Family

ID=51261317

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015555498A Expired - Fee Related JP6539585B2 (ja) 2013-02-01 2014-01-31 抗cd83抗体及びその使用
JP2019000340A Pending JP2019076102A (ja) 2013-02-01 2019-01-04 抗cd83抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019000340A Pending JP2019076102A (ja) 2013-02-01 2019-01-04 抗cd83抗体及びその使用

Country Status (13)

Country Link
US (3) US9840559B2 (https=)
EP (2) EP3626743A1 (https=)
JP (2) JP6539585B2 (https=)
KR (2) KR102204127B1 (https=)
CN (1) CN105531289B (https=)
AU (1) AU2014213009B2 (https=)
CA (1) CA2899960C (https=)
DK (1) DK2951208T3 (https=)
ES (1) ES2762622T3 (https=)
MX (1) MX2015010023A (https=)
NZ (1) NZ711543A (https=)
PT (1) PT2951208T (https=)
WO (1) WO2014117220A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840559B2 (en) 2013-02-01 2017-12-12 The Regents Of The University Of California Anti-CD83 antibodies and use thereof
WO2016061617A1 (en) * 2014-10-23 2016-04-28 Dendrocyte Biotech Pty Ltd Cd83 binding proteins and uses thereof
EP3681536A4 (en) * 2017-09-13 2021-06-09 Kira Biotech Pty Limited TREATMENT METHOD
KR20200130324A (ko) 2018-02-23 2020-11-18 에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨 Cd83-결합 키메라 항원 수용체
PH12022550141A1 (en) 2019-07-19 2023-12-04 Oncoresponse Inc Immunomodulatory antibodies and methods of use thereof
JP7701908B2 (ja) * 2019-08-16 2025-07-02 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド 抗cd38キメラ抗原受容体を発現する制御性t細胞
WO2022191550A1 (ko) * 2021-03-09 2022-09-15 (주)지아이이노베이션 IgE Fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 융합단백질의 제형
CN117547553A (zh) * 2023-11-21 2024-02-13 中国人民解放军陆军特色医学中心 Cd83+、cd83+pd-l1+间充质干细胞及其制备方法和应用

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593089A (en) 1980-07-30 1986-06-03 Abbott Laboratories Fluorescent polarization immunoassay utilizing substituted triazinylaminofluorescein aminoglycosides
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4751190A (en) 1985-07-22 1988-06-14 Abbott Laboratories Fluorescence polarization immunoassay and reagents for use therein
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ATE82588T1 (de) 1986-04-28 1992-12-15 Endotronics Inc Zuchtverfahren fuer leukocyten.
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
DE4211351A1 (de) 1992-04-04 1993-10-07 Behringwerke Ag Verfahren zur Analyse partikelverstärkter Agglutinationsreaktionen auf Zentrifugalanalysatoren durch Bestimmung der Trübungsaufhellung
AU3691093A (en) 1992-04-14 1993-10-21 Hybritech Incorporated Methods of inhibiting the growth of multidrug resistant tumors
US5316920A (en) 1992-04-17 1994-05-31 Dana-Faber Cancer Institute, Inc. Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily
US5710262A (en) 1992-04-17 1998-01-20 Dana-Faber Cancer Institute, Inc. Nucleic acid encoding HB15 polypeptides
SG41929A1 (en) 1992-09-25 1997-08-15 Commw Scient Ind Res Org Target binding polypeptide
US20080152586A1 (en) 1992-09-25 2008-06-26 Avipep Pty Limited High avidity polyvalent and polyspecific reagents
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6541213B1 (en) 1996-03-29 2003-04-01 University Of Washington Microscale diffusion immunoassay
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
CA2244326C (en) 1997-08-11 2006-03-28 Shinichi Eda Microparticle enhanced light scattering agglutination assay and microparticle reagents therefor
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US6562622B1 (en) 1998-05-08 2003-05-13 Diatech Pty, Ltd Continuous in vitro evolution
WO2000034317A2 (en) 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2000042430A1 (en) 1999-01-15 2000-07-20 Medtox Scientific, Inc. Lateral flow test strip
AU781547B2 (en) * 1999-04-14 2005-05-26 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions containing immunotoxins and agents that inhibit dendritic cell maturation for inducing immune tolerance to a graft
US7270969B2 (en) 1999-05-05 2007-09-18 Phylogica Limited Methods of constructing and screening diverse expression libraries
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US7205159B2 (en) 2001-08-20 2007-04-17 Proteome Systems Intellectual Property Pty Ltd. Diagnostic testing process and apparatus
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20040185040A1 (en) 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
JP2005519586A (ja) * 2001-11-21 2005-07-07 セルテック アール アンド ディー, インコーポレイテッド Cd83遺伝子産物を利用したサイトカイン・レベルの操作法
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2002950779A0 (en) 2002-08-15 2002-09-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland A method of immunomodulation
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004048552A2 (en) * 2002-11-21 2004-06-10 Celltech R & D, Inc. Modulating immune responses
JP2006507510A (ja) 2002-11-21 2006-03-02 インバーネス・メデイカル・スウイツツアーランド・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング 組織低酸素症の体液マーカー
US7169898B2 (en) * 2002-12-04 2007-01-30 Alexander Steinkasserer Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス,インコーポレーテッド 変異型Fc領域を含む抗体の同定および作製ならびにその利用法
AU2004245038A1 (en) 2003-06-02 2004-12-16 Alexion Pharmaceuticals, Inc. De-immunized anti-CD3 antibody
JP2007531707A (ja) 2003-10-15 2007-11-08 ピーディーエル バイオファーマ, インコーポレイテッド IGの重鎖定常領域の位置250、314および/または428の変異誘発によるFc融合タンパク質血清半減期の改変
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006063150A2 (en) * 2004-12-08 2006-06-15 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
US20090247455A1 (en) 2005-03-31 2009-10-01 Mark Fear Isolation of Inhibitors of IRES-Mediated Translation
CN101155914B (zh) * 2005-04-08 2013-03-06 阿戈斯治疗公司 树状细胞组合物和方法
KR20080068004A (ko) 2005-08-15 2008-07-22 아라나 테라퓨틱스 리미티드 뉴 월드 영장류 구조형성영역을 가진 조작 항체
WO2007150020A1 (en) * 2006-06-23 2007-12-27 Simon Paul M Targeted immune conjugates
EP1985305A1 (en) 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
EP2207803B1 (en) 2008-06-25 2013-05-01 Korea Research Institute of Bioscience and Biotechnology Cd9-specific human antibodies
AR074369A1 (es) 2008-11-20 2011-01-12 Genentech Inc Anticuerpos anti-unc 5b (receptor de netrina) y metodos de uso
WO2012088290A2 (en) * 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
JP2013040160A (ja) * 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗cd83アゴニスト抗体の使用
US9840559B2 (en) 2013-02-01 2017-12-12 The Regents Of The University Of California Anti-CD83 antibodies and use thereof
WO2016061617A1 (en) 2014-10-23 2016-04-28 Dendrocyte Biotech Pty Ltd Cd83 binding proteins and uses thereof
EP3681536A4 (en) 2017-09-13 2021-06-09 Kira Biotech Pty Limited TREATMENT METHOD

Similar Documents

Publication Publication Date Title
JP2016507521A5 (https=)
TWI883026B (zh) 抗dll3嵌合抗原受體及其用途
JP2023071684A (ja) 抗bcma重鎖のみ抗体
JP2012501670A5 (https=)
CN112955470A (zh) 抗tnfr2抗体及其用途
CN109563170B (zh) 抗gitr抗体及其用途
TW201031421A (en) IL-1 binding proteins
WO2018137576A1 (zh) 抗pd-1单克隆抗体及其制备方法和应用
JP2012526558A5 (https=)
KR20180083944A (ko) 항체 및 이의 사용 방법
TW201134487A (en) Therapeutic DLL4 binding proteins
JP7796034B2 (ja) ヒトcd45rcに特異的なキメラ抗原受容体およびその使用
JP2017530119A (ja) リンパ球における阻害経路の中和
ES2737307T3 (es) Anticuerpos no antagonistas dirigidos contra la cadena alfa del dominio extracelular del receptor de IL7 y uso del mismo en el tratamiento del cáncer
KR20120104542A (ko) Il?1 결합 단백질
CN101512008A (zh) 白介素-13结合蛋白
WO2012125680A1 (en) Methods of treating vasculitis using an il-17 binding molecule
AU2020328931A1 (en) Antibodies against ILT2 and use thereof
US12071479B2 (en) Antibodies against ILT2 and use thereof
CN113278071B (zh) 抗人干扰素α受体1单克隆抗体及其应用
CA3188068A1 (en) Multispecific binding agents and uses thereof
CN109071660A (zh) 预防移植物抗宿主疾病的方法
WO2022031680A1 (en) Cd47 binding agents and uses thereof
US20230303699A1 (en) Pd-l1 binding agents and uses thereof
JP2024512252A (ja) Cd47に対する単一ドメイン抗体及びその用途